In 3-KO mice, these reductions were absent, reinforcing the idea that 3-AR plays a necessary role in regulating the response of brown adipose tissue to these agents [2]
But AOD 9604 makes those efforts more effective at actually burning fat rather than just losing weight (which often includes muscle)
By the mid-2000s, the obesity pharmacotherapy field expected at least 5% placebo-subtracted weight loss for regulatory consideration, a threshold later codified in FDA's 2007 guidance for industry on developing obesity drugs
AOD 9604 clinical trials showed a tolerability profile statistically indistinguishable from placebo
Early work focused on the hGH fragment 177191, which was later modified by adding a tyrosine residue, leading to the development of AOD 9604
Therapeutic peptides are designed to treat specific medical conditions, while synthetic peptides are created to mimic the structure and function of natural peptides